PalaciosS, MejiaA, NeyroJL. Treatment of the genitourinary syndrome of menopause. Climacteric, 2015; 18Suppl 1:23–29.
2.
PortmanDJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus ConferencePanel. Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Climacteric, 2014; 17:557–563.
3.
GandhiJ, ChenA, DagurG, et al.Genitourinary syndrome of menopause: An overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol, 2016; 215:704–711.
4.
FernandesT, Costa-PaivaLH, PedroAO, BaccaroLF, Pinto-NetoAM. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: A randomized controlled trial. Menopause, 2016; 23:792–798.
NappiRE, PalaciosS. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric, 2014; 17:3–9.
7.
North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause, 2007; 14:355–369.
8.
SturdeeDW, Panay N; International Menopause Society WritingGroup. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric, 2010; 13:509–522.
9.
Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause, 2013; 20:888–902.
10.
DiemSJ, GuthrieKA, MitchellCM, et al.Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: A randomized clinical trial. Menopause, 2018; 25:1086–1093.
11.
SucklingJ, LethabyA, KennedyR. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev, 2006:CD001500.
12.
LabrieF, ArcherDF, KoltunW, et al.Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause, 2016; 23:243–256.
LabrieF, ArcherD, BouchardC, et al.High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecol Endocrinol, 2010; 26:524–532.
LabrieF, ArcherDF, BouchardC, et al.Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas, 2015; 81:46–56.
17.
LabrieF, Luu-TheV, MartelC, et al.Dehydroepiandrosterone (DHEA) is an anabolic steroid like dihydrotestosterone (DHT), the most potent natural androgen, and tetrahydrogestrinone (THG). J Steroid Biochem Mol Biol, 2006; 100:52–58.
18.
LabrieF, ArcherDF, BouchardC, et al.Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric, 2011; 14:282–288.
19.
BergerL, El-AlfyM, MartelC, LabrieF. Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina. J Steroid Biochem Mol Biol, 2005; 96:201–215.
20.
PelletierG, OuelletJ, MartelC, LabrieF. Androgenic action of dehydroepiandrosterone (DHEA) on nerve density in the ovariectomized rat vagina. J Sex Med, 2013; 10:1908–1914.
21.
BaberR. Breast cancer in postmenopausal women after hormone therapy. JAMA, 2011; 305:466; author reply 466–467.
22.
ArcherDF, LabrieF, BouchardC, et al.Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause, 2015; 22:950–963.
23.
PalaciosS, CanceloMJ. Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy. Int J Womens Health, 2016; 8:617–626.
24.
PinkertonJ.FDA mandating vaginal laser manufacturers present. Valid data before marketing. August 1, 2018.
